Executives seek “skin in the game” despite signs of a stock market cooldown.
Written by Nikkei Asia
Published on
7 May 2026
3 mins read
Global pharmaceutical executives are hungry for more deals with Chinese biotechnology companies after a record year, even as a stock market boom shows signs of cooling down.
Such deals allow Chinese firms to profit while minimising capital outlays, but also carry risks, law firm says.
Chinese biotech firms are striking big global deals as drug makers, but could artificial intelligence take them to the next level?
Bristol Myers’ alliance with Hengrui ranks as the second-largest licensing pact of its kind since the start of 2025, trailing…
China biotech remains a market bright spot with strong growth, driven by out-licensing, efficiency improvements and cost control.
Chinese drug makers are increasingly relying on overseas licensing deals to reach global markets amid growing geopolitical…
The veteran investor says that the trove of ready-made prospects is making the global biotech ecosystem “more competitive” and…
